Damora TherapeuticsDMRA
13F holders, Q4 2025 (December 31)18holders +6
10new positions
6sold out
1famous investor
$59.09avg. 13F price*
At the end of Q4 2025, 18 institutions reported holding Damora Therapeutics Inc. (DMRA) in their 13F filings, up 6 from Q3 2025. 10 opened new positions and 6 sold out. The largest holders were Janus Henderson Group PLC ($40.0M), Ikarian Capital, LLC ($6.6M) and FMR LLC ($5.5M). One famous investor held it Steve Cohen (0.0% of Point72 Asset Management's portfolio).
- Company
- Damora Therapeutics Inc.
- Filed as
- GALECTO INC (Q4 2025)
- CUSIP
- 36322Q206
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 10 | $62.3M |
| Exits | 6 | $603K |
All 13F filers, Q3 2025 → Q4 2025: 985,762 shares bought and 168,585 shares sold, net +817,177 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| Janus Henderson Group PLC | 0.02% | New | 1,739 | $40.0M |
| Ikarian Capital, LLC | 0.85% | New | 285,710 | $6.6M |
| FMR LLC | 0.00% | New | 238,878 | $5.5M |
| Jain Global LLC | 0.03% | New | 120,566 | $2.8M |
| Remedium Capital Partners, LLC | 1.63% | — | 120,473 | $2.8M |
| Point72 Asset Management | 0.00% | New | 109,000 | $2.5M |
| Boothbay Fund Management, LLC | 0.06% | New | 95,798 | $2.2M |
| Morgan Stanley | 0.00% | New | 74,917 | $1.7M |
| Vanguard Group Inc. | 0.00% | New | 18,247 | $420K |
| Sigma Planning Corp | 0.01% | New | 14,500 | $334K |
| Geode Capital Management, LLC | 0.00% | New | 11,573 | $266K |
| BlackRock, Inc. | 0.00% | Add +7420.0% | 7,520 | $173K |
| UBS Group AG | 0.00% | Add +10728.8% | 6,389 | $147K |
| Bank of America Corp. | 0.00% | Reduce -81.1% | 1,228 | $28K |
| Citigroup Inc. | 0.00% | Add +2520.9% | 1,127 | $26K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -87.7% | 176 | $4K |
| SHP Wealth Management | 0.00% | — | 25 | $575 |
| SBI Securities Co., Ltd. | 0.00% | Reduce -22.2% | 14 | $322 |
"% of holder's portfolio" is DMRA's weight in each manager's 13F, not the share of Damora Therapeutics Inc. the manager owns.